Phase II Trial of 9-Aminocamptothecin as a 72-h Infusion in Cutaneous T-Cell Lymphoma

[1]  D. Moore,et al.  Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma , 1998, Investigational New Drugs.

[2]  P. Houghton,et al.  Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors , 2004, Cancer Chemotherapy and Pharmacology.

[3]  F. Foss,et al.  Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T‐cell lymphoma , 1999, Cancer.

[4]  J. Verweij,et al.  Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Schellens,et al.  Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Ratain,et al.  Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  E. Estey,et al.  Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  M. Kashani-Sabet,et al.  Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. , 1999, Journal of the American Academy of Dermatology.

[9]  M. Ratain,et al.  Pharmacokinetics and Pharmacodynamics of 9-Aminocamptothecin Infused Over 72 Hours in Phase II Studies 1 , 1999 .

[10]  P. Quaglino,et al.  Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. , 1998, Leukemia & lymphoma.

[11]  M. Ratain,et al.  A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  W. Wilson,et al.  Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Bernstein,et al.  Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Eisenhauer,et al.  Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Moore,et al.  Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma. , 1998, Investigational new drugs.

[16]  L. Grochow,et al.  Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants , 1998, Cancer Chemotherapy and Pharmacology.

[17]  R. Schilsky,et al.  Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071) , 1998, Cancer Chemotherapy and Pharmacology.

[18]  S. Arbuck,et al.  Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Arbuck,et al.  Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Rosen,et al.  Chemotherapy for mycosis fungoides and the Sézary syndrome. , 1995, Hematology/oncology clinics of North America.

[21]  D. Toppmeyer,et al.  A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  L. Golitz,et al.  Systemic Therapy of Cutaneous T-Cell Lymphomas (Mycosis Fungoides and the Sezary Syndrome) , 1994, Annals of Internal Medicine.

[23]  Y. Ohashi,et al.  [Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies]. , 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

[24]  P. Houghton,et al.  Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. , 1993, Cancer research.

[25]  D. V. Von Hoff,et al.  Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. , 1992, Journal of the National Cancer Institute.

[26]  E. Vonderheid,et al.  Infections complicating mycosis fungoides and Sézary syndrome. , 1992, JAMA.

[27]  S. Steinberg,et al.  A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. , 1989, The New England journal of medicine.

[28]  L. Liu,et al.  DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. , 1989, Science.